Ocugen今日宣布，美国食品药品监督管理局（FDA）已正式授予其管线药物Ocu410“再生医学先进疗法”（RMAT）认定。该疗法旨在治疗干性年龄相关性黄斑变性（AMD）所继发的地图状萎缩（GA）——一种导致不可逆视力丧失的严重眼科疾病。
Ocugen今日宣布，美国食品药品监督管理局（FDA）已正式授予其管线药物Ocu410“再生医学先进疗法”（RMAT）认定。该疗法旨在治疗干性年龄相关性黄斑变性（AMD）所继发的地图状萎缩（GA）——一种导致不可逆视力丧失的严重眼科疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.